New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
09:28 EDTGILD, CNCCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Sterne Agee believes that Centene (CNC) is the best positioned among the health insurance companies focusing on Medicaid to beat the consensus Q2 EPS outlook. The firm thinks that increased revenue from Centene's specialty pharmacy unit may have more than offset its increased costs from Gilead's (GILD) Sovaldi in Q2. The firm keeps a Buy rating on Centene.
News For CNC;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 17, 2014
09:41 EDTGILDActive equity options trading
Subscribe for More Information
December 16, 2014
16:00 EDTGILDOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
08:13 EDTCNCCentene price target raised to $125 from $108 at Cantor
Subscribe for More Information
07:57 EDTCNCCentene price target raised to $118 from $102 at Credit Suisse
Subscribe for More Information
December 15, 2014
08:41 EDTCNCCentene price target raised to $120 from $100 at Leerink
Subscribe for More Information
December 12, 2014
09:35 EDTGILDActive equity options trading
Subscribe for More Information
06:06 EDTCNCCentene sees FY15 EPS $5.05-$5.35, consensus $4.92
Sees FY15 premium and service revenues $20.3B-$20.8B.
06:05 EDTCNCCentene backs FY14 EPS view of $4.35-$4.50, consensus $4.28
Subscribe for More Information
December 11, 2014
16:01 EDTGILDOptions Update; December 11, 2014
Subscribe for More Information
11:55 EDTGILDGilead shares look cheap, poised for growth, Barron's says
Subscribe for More Information
07:54 EDTGILDGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
December 10, 2014
15:59 EDTGILDGilead sued by SEPTA over price of Hep C drug Sovaldi, WSJ reports
Subscribe for More Information
14:45 EDTCNCDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
December 9, 2014
10:31 EDTCNCCentene to host investor meeting
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
08:38 EDTGILDGilead price target raised to $130 from $110 at Argus
Subscribe for More Information
December 8, 2014
16:00 EDTGILDOptions Update; December 8, 2014
Subscribe for More Information
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information
December 5, 2014
09:36 EDTGILDActive equity options trading
Subscribe for More Information
07:37 EDTGILDGilead price target raised to $121 from $110 at JPMorgan
JPMorgan raised its price target for Gilead shares to $121 saying the company's potential cash flow generation is "immense" and provides "significant strategic flexibility." The firm estimates Gilead can generate more than $30B in cash in the next two years and $80B-plus over the next five years. It keeps an Overweight rating on the stock.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use